Recruiting
Phase 1
Phase 2

MSH2IA

Sponsor:

Imagion Biosystems, Inc.

Code:

NCT07885683

Conditions

HER2-positive Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

The MagSense® HER2 Imaging Agent (MSH2IA)

Study Details

Brief summary:

This Phase 1b/2 study is designed as an open-label, multicenter, 3 group, interventional study in which Phase 1b will evaluate the pharmacokinetics (PK) of MSH2IA and Phase 2 will confirm lowest effective dose as well as evaluate image timing, and diagnostic performance of a selected dose of MSH2IA when administered by subareolar or peritumoral injection.

No hypothesis testing is planned. Comparative statistics will be used to generate hypotheses to be tested in subsequent studies.

Conditions

HER2-positive Breast Cancer

Study ID

NCT07885683

Start date

Nov 30, 2026

Status verified date

Nov, 2026

Completion date

Jul 23, 2029

Anticipated

Primary completion date

Jan 31, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Female participants ≥18 years of age and are willing to provide written informed consent.
2. In the opinion of the Investigator, willing and able to comply with required study procedures.
3. Histologically confirmed primary HER2+ breast cancer; participants with a second primary tumor in the contralateral breast are eligible, but only 1 side will be evaluated.
4. Primary tumor must be HER2+, defined according to ASCO/CAP 2018 guidelines as either IHC 3+ or IHC 2+ with confirmatory ISH-positive.
5. Phase 1b and Phase 2 (Imaging Schedule) participants must be node suspicious by SOC assessment.
6. No previous treatment of the primary tumor or ipsilateral axilla that includes surgery (other than biopsy), radiotherapy, or a biologic such as trastuzumab. In Phase 2 (Diagnostic Performance) only, participants who have received NCT are eligible if treatment has not included trastuzumab.
7. Female participants of nonchildbearing potential: defined as either surgically sterilized (eg, hysterectomy, bilateral salpingectomy, bilateral oophorectomy ≥6 weeks before screening) or postmenopausal (ie, no menses for 12 months without an alternative medical cause.
8. Female participants of childbearing potential are eligible to participate if not pregnant, not breastfeeding, and using birth control.

Exclusion Criteria:

Participants will be excluded from the study if ANY of the following criteria are applicable:

1. Contraindications to the use of the Magtrace™ and Sentimag® Magnetic Localization System (Magtrace 2018), including use before NCT when MRI will be the primary imaging method for evaluation of breast cancer
2. Previous or current diseases of Fe metabolism or history of adverse reactions to intravenous Fe products
3. Known hypersensitivity to trastuzumab, iron oxide, or polyethylene glycol compounds
4. Treatment by Herceptin® or biosimilar within prior six months
5. Planned or prior use of Magtrace™ and Sentimag as a diagnostic agent, as it might interfere with MagSense® evaluations
6. Known clinical or radiological evidence of distant metastases (Stage IV disease)
7. Inflammatory breast cancer
8. Prior surgical axillary procedure, including SLNB or ALND, or previous radiation on the ipsilateral side of the breast cancer primary
9. Prior history of breast cancer in the ipsilateral breast
10. Metal devices or fragments other than post-breast biopsy clips in the ipsilateral axilla or in the ipsilateral chest
11. Any contraindications to MRI imaging

Study Design

Enrollment

70 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Phase 1b - MSH2IA Pharmacokinetics

Participants enrolled in Phase 1b will receive MSH2IA to evaluate its pharmacokinetic (PK) profile.

experimental: Phase 2 - MSH2IA Dose and Diagnostic Performance

Participants enrolled in Phase 2 will receive MSH2IA via subareolar or peritumoral injection to confirm the lowest effective dose, evaluate image timing, and assess the diagnostic performance of a selected dose of MSH2IA.

Interventions

The MagSense® HER2 Imaging Agent (MSH2IA)

Imaging Agent intended as an adjunct to MRI for the assessment of axillary nodal disease in participants diagnosed with HER2+ primary breast cancer.

Primary outcome measure

  • Phase 1b: Level of Fe in blood [ Time Frame: 24 hours post injection ]
  • Phase 2 (Imaging Schedule): Dose and Imaging schedule for MSH2IA [ Time Frame: 24 hours post injection ]
  • Phase 2 (Diagnostic Performance): Diagnostic performance comparison between MSH2IA and SOC [ Time Frame: 24 hours post injection ]

Central Contacts and Locations

Central contacts

Locations

Regis Clinical Research LLC

Recruiting

Miami, Florida, United States, 33126

Contacts

Principal Investigator:

Yilena Rodriguez Marrero, MD

More Information

Sponsor

Imagion Biosystems, Inc.

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Imagion Biosystems, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.